Please login to the form below

Not currently logged in
Email:
Password:

MNK-795

This page shows the latest MNK-795 news and features for those working in and with pharma, biotech and healthcare.

Mallinckrodt offers $1.3bn for Cadence Pharma

company.". Mallinckrodt is also active in the analgesia sector and last year won priority review status from the FDA for MNK-795, a controlled-release oral formulation of oxycodone and acetaminophen

Latest news

  • FDA grants priority review to pain drug

    FDA grants priority review to pain drug. Mallinckrodt’ s MNK-795 is intended for the management of moderate to severe acute pain. ... Mallinckrodt has won priority review from the US Food and Drug Administration (FDA) for its pain drug MNK-795.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics